Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Collaboration combines Gate Bioscience's Molecular Gate drug discovery engine with Lilly's expertise in small molecule therapeutics. Company to receive an upfront payment, an equity investment, ...

Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...

The gene therapy developer is cutting 30% of its workforce. Elsewhere, Abivax secured a major cash infusion, while Novartis and Eli Lilly struck research deals.

U.S. pharmaceutical company Eli Lilly (LLY) has partnered with Juvena Therapeutics on a new muscle-boosting drug. Confident Investing Starts Here: Easily unpack a company's performance with ...

The stock of Eli Lilly has a consensus Strong Buy recommendation among 18 Wall Street analysts. That rating is based on 16 Buy, one Hold, and one Sell recommendations issued in the last 12 months.